Targeted therapeutics designed to address
unmet needs in immune-mediated diseases

We have a robust pipeline of therapeutic development programs to address several
clinical IBD patient subpopulations, and plan to develop a companion diagnostic for
each program.

Prometheus Biosciences therapeutic pipeline

Lead Optimization
Phase 1
Phase 2
Phase 3
PRA023 Anti-TL1A mAb
for Ulcerative Colitis
PRA023 Anti-TL1A mAb
for Crohn’s Disease
PRA023 Anti-TL1A mAb
for SSc-ILD
PR600* Anti-TNF super family member mAb
for IBD
PR300 GPCR modulator small molecule
for IBD
PR1100 Novel antibody target mAb
for IBD
PR1800 Anti-chemokine mAb
for IBD
PR2100 Anti-inflammatory cytokine mAb
for IBD

*Partnered with Dr. Falk Pharma in Europe, Australia, and New Zealand

See the promise of PRA023

Learn more about TL1A

Strategic collaborations and partnerships

To advance our game-changing precision medicines platform, we have forged partnerships with pharmaceutical companies, foundations, and academic groups with critical gastrointestinal (GI) area expertise and resources. This approach has accelerated the application of our technology and enabled us to secure necessary funding to advance our development progress.

Our partners include Cedars-Sinai Medical Center, University of California San Diego, Takeda Pharmaceutical Company, and Dr. Falk Pharma GmbH.

Partnership inquiries

We strive to be the partner of choice in gastrointestinal (GI) and immune-mediated diseases by applying our technology and utilizing the Prometheus360™ platform to advance clinical programs. For inquiries or to learn more, please contact us.

Prometheus Biosciences
9410 Carroll Park Dr.
San Diego, CA 92121
[email protected]